Page last updated: 2024-11-12

psymberin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

psymberin: from the Indo-Pacific marine sponge Ircinia ramosa; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11692946
CHEBI ID182709
SCHEMBL ID13496618
MeSH IDM0482618

Synonyms (14)

Synonym
(2s,3s)-n-[(s)-[(2s,4r,6r)-6-[(2s,3r)-3-[(3r)-6,8-dihydroxy-5-methyl-1-oxo-3,4-dihydroisochromen-3-yl]-2-hydroxybutyl]-4-hydroxy-5,5-dimethyloxan-2-yl]-methoxymethyl]-2-hydroxy-3-methoxy-5-methylhex-5-enamide
CHEBI:182709
psymberin
SCHEMBL13496618
714954-37-7
5-hexenamide, n-((s)-((2s,4r,6r)-6-((2s,3r)-3-((3r)-3,4-dihydro-6,8-dihydroxy-5-methyl-1-oxo-1h-2-benzopyran-3-yl)-2-hydroxybutyl)tetrahydro-4-hydroxy-5,5-dimethyl-2h-pyran-2-yl)methoxymethyl)-2-hydroxy-3-methoxy-5-methyl-, (2s,3s)-
sak6w44zup ,
(+)-irciniastatin a
(+)-iriciniastatin a
(2s,3s)-n-((s)-((2s,4r,6r)-6-((2s,3r)-3-((3r)-3,4-dihydro-6,8-dihydroxy-5-methyl-1-oxo-1h-2-benzopyran-3-yl)-2-hydroxybutyl)tetrahydro-4-hydroxy-5,5-dimethyl-2h-pyran-2-yl)methoxymethyl)-2-hydroxy-3-methoxy-5-methyl-5-hexenamide
(+)-psymberin
psymberin, (+)-
DTXSID301098104
(2s,3s)-n-[(s)-[(2s,4r,6r)-6-[(2s,3r)-3-[(3r)-3,4-dihydro-6,8-dihydroxy-5-methyl-1-oxo-1h-2-benzopyran-3-yl]-2-hydroxybutyl]tetrahydro-4-hydroxy-5,5-dimethyl-2h-pyran-2-yl]methoxymethyl]-2-hydroxy-3-methoxy-5-methyl-5-hexenamide
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
hydroxybenzoic acidAny benzoic acid carrying one or more phenolic hydroxy groups on the benzene ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (32)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's15 (46.88)29.6817
2010's17 (53.13)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews3 (9.38%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other29 (90.63%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]